On December 2, 2021, BD (bidi company) announced that it had acquired venclose company. The solution provider is used to treat chronic venous insufficiency (CVI), a disease caused by valve dysfunction, which can lead to varicose veins.
Radiofrequency ablation is the main treatment for CVI and is widely accepted by doctors. Compared with the alternative laser treatment of CVI, radiofrequency catheter ablation can potentially reduce postoperative pain and bruising. Vinclose is a leader in the field of CVI therapy. Its innovative radio frequency (RF) ablation technology platform aims to achieve versatility, efficiency and simplicity.
Extended vein ablation line
CVI represents a significant and growing need for treatment within the healthcare system - affecting up to 40% of women and 17% of men in the United States. Vinclose is a leader in the field of CVI therapy. Its innovative radio frequency (RF) ablation technology platform aims to achieve versatility, efficiency and simplicity. Radiofrequency ablation is the main treatment for CVI and is widely accepted by doctors. Compared with the alternative laser treatment of CVI, radiofrequency catheter ablation can potentially reduce postoperative pain and bruising.
"We are committed to setting a new standard of excellence for patients with venous diseases, which first needs to provide innovative technologies for doctors," said paddy O'Brien, global president of BD peripheral intervention. "Our acquisition of venclose will enable us to provide a more powerful portfolio of solutions for doctors who treat a variety of venous diseases. Venclose ™ The radiofrequency ablation system strategically complements our leading portfolio of venous disease technologies and is aligned with our focus to innovate and provide transformative solutions to improve the treatment of chronic diseases and make the transition to a new nursing environment possible. "
Venclose ™ The compact design of the system provides two heating length sizes (2.5 cm and 10 cm) in a 6 Fr size catheter. This dynamic double heated length catheter provides doctors with a variety of operational advantages.
Venclose ™ The heating length of the system is 30% longer than that of the longest leading competitive radiofrequency ablation catheter, enabling doctors to effectively ablate more veins in each heating cycle and helping to reduce the total number of ablations required for intravenous therapy. Dual heating lengths mean that doctors can use the same catheter to ablate long and short venous segments - reducing the burden of inventory management compared to catheters with shorter and / or static heating length sizes.
The technology of the system is also designed to help provide a patient-centered approach to care. For example, its touch-screen display provides real-time program data to help inform doctors of treatment decisions. The system also provides an audible tone for heat transfer - allowing the doctor to focus more time and attention on the patient.
Vinclose was established in 2014 to enhance the treatment of CVI through radiofrequency ablation technology. Since then, the company has been committed to providing technical progress and procedural efficiency for doctors who treat CVI, while also helping to improve patient satisfaction. Venclose ™ The system can be used in various health care institutions in the United States and Europe. The terms of the transaction were not disclosed. The transaction is expected to be insignificant to BD's financial performance in fy2022.
Ten billion market
In 2020, the global peripheral vascular medical device market is expected to reach US $8.92 billion (equivalent to RMB 56.8 billion), and the United States is still the largest market in the world. Venous intervention is a part of the peripheral intervention market, and the domestic venous intervention market is growing rapidly. In 2013, the market scale of venous interventional devices in China was only 370million yuan. In 2017, the market scale of venous intervention has increased to RMB 890million. This rapid growth trend will rise rapidly with the growth of venous intervention in clinical application. By 2022, the market scale will reach RMB 3.1 billion, with an annual compound growth rate of 28.4%.
According to statistics, 100000-300000 people die of venous thrombosis every year in the United States, and 500000 people die of venous thrombosis every year in Europe. In 2019, the number of varicose vein patients in China reached 390million; There are 1.5 million patients with deep venous thrombosis; The incidence rate of iliac vein compression is 700000 and is expected to reach 2million by 2030.
With the intensive collection of coronary stents, the focus of vascular intervention shifted from coronary artery to neurovascular and peripheral vessels. Peripheral intervention includes peripheral arterial intervention and peripheral venous intervention. Venous intervention started late but developed rapidly. According to the calculation of industrial securities, the market value of China's venous interventional devices mainly for the treatment of common venous diseases such as varicose veins, deep venous thrombosis and iliac vein compression syndrome is about 19.46 billion.
This peripheral market, which will exceed 10 billion yuan in scale, has attracted multinational giants such as BD, Medtronic and Boston science. They have entered the market early, have large enterprises and have formed a rich product line. Local enterprises have also risen one after another. Enterprises such as Xianjian technology and guichuang Tongqiao have reserved rich R & D pipelines in the vein field.
Domestic vein ablation pattern
With the standardization of minimally invasive surgery for varicose veins, minimally invasive therapy will replace traditional surgery, and the volume of surgery will further increase rapidly. Among the minimally invasive therapies, radiofrequency ablation (RFA) and intracavitary laser ablation (EVLA) are two proven ablation methods. RFA accounts for more than 70% of intracavitary thermal ablation in China in 2019. At present, there are two approved radiofrequency ablation systems in China. There are mainly three peripheral radiofrequency ablation catheters on sale in China, which are made by foreign enterprises, namely, closure fast and closure RFs of Medtronic and evrf intravenously radiofrequency closure system of F care systems NV.
The innovation direction of radiofrequency ablation products focuses on reducing complications. The main complications of existing radiofrequency ablation products are skin burns, vein splitting, subcutaneous ecchymosis and swelling, and saphenous nerve injury. Energy control, subcutaneous injection of swelling fluid and continuous pressure therapy can effectively reduce the occurrence of complications. Thermal ablation requires tumescent anesthesia before energy delivery, which may cause discomfort to the patient and may prolong the operation time.
For this reason, Medtronic has focused on venaseal, a normal temperature closure product. The principle of this closure system is to use a catheter to inject adhesive into the vein to achieve the effect of closing the vein. Venaseal was approved by FDA for listing in 2015. In recent years, it has become the main growth point of Medtronic's peripheral business. At present, this product has not been listed in China.
At present, domestic enterprises focus on the localization of radiofrequency ablation products for varicose vein ablation and reduce the complications of thermal ablation products; The adjustable, controllable and intelligent radiofrequency ablation system will greatly reduce the difficulty of operation, and is an important direction of product improvement. Domestic R & D enterprises of radiofrequency ablation products include xianruida and guichuangtong bridge. Unsatisfied market demand drives many enterprises to gather at this track, and the competition in this field will become fierce in the future.
From the perspective of domestic participants, the competition pattern of domestic vein intervention market has also initially emerged. The main participants include multinational enterprises represented by Medtronic, Boston science and bidi medical; Domestic leaders represented by xianruida and Xinmai medical, as well as a number of emerging start-ups.
Post time: Jun-28-2022